Literature DB >> 8187681

Examination of the segmental pathophysiological mechanisms of spasticity.

I Milanov1.   

Abstract

The purpose of this investigation was to ascertain a complex of electromyographic methods suitable for evaluation of the basic segmental pathophysiological mechanisms of spasticity. Clinical and electromyographic examinations were performed on 120 patients with spastic hemiparesis after stroke. Patients muscle tone, muscle force and tendon reflexes were assessed by the well known clinical five point scales. A battery of electromyographic methods was used to analyze different segmental mechanisms of spasticity: for alpha motoneurone activity--the F-wave parameters; for gamma motoneurone activity--the TA/H amplitude ratio; for common interneurone activity--the flexor reflex parameters; for presynaptic inhibition--the Hvibrated/Hmaximal amplitude ratio. Our results revealed that nearly all of the patients have increased alpha motoneurone activity on the spastic side. In most of the patients at least two of the segmental mechanisms are altered. Different mechanisms participate with different frequency in development of spasticity. We suppose that alpha-motoneurone hyperactivity usually develops secondary after alteration of some other segmental mechanism. In conclusion the applied complex of electromyographic methods gives the possibility for evaluation of the individual pathophysiological profile of patients with spasticity. This is a background for appropriate treatment.

Entities:  

Mesh:

Year:  1994        PMID: 8187681

Source DB:  PubMed          Journal:  Electromyogr Clin Neurophysiol        ISSN: 0301-150X


  9 in total

1.  Short-term effects of thermotherapy for spasticity on tibial nerve F-waves in post-stroke patients.

Authors:  Shuji Matsumoto; Kazumi Kawahira; Seiji Etoh; Satoshi Ikeda; Nobuyuki Tanaka
Journal:  Int J Biometeorol       Date:  2005-12-22       Impact factor: 3.787

2.  Nitrous oxide can enhance the hypnotic effect, but not the suppression of spinal motor neuron excitability by propofol in humans.

Authors:  Manabu Kakinohana; Yuji Miyata; Hiroshi Tomiyama; Kazuhiro Sugahara
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

3.  Beneficial effects of footbaths in controlling spasticity after stroke.

Authors:  Shuji Matsumoto; Megumi Shimodozono; Seiji Etoh; Yurika Shimozono; Nobuyuki Tanaka; Kazumi Kawahira
Journal:  Int J Biometeorol       Date:  2010-02-17       Impact factor: 3.787

Review 4.  Chapter 11--novel mechanism for hyperreflexia and spasticity.

Authors:  C Yates; K Garrison; N B Reese; A Charlesworth; E Garcia-Rill
Journal:  Prog Brain Res       Date:  2011       Impact factor: 2.453

5.  Activity-dependent depression of the recurrent discharge of human motoneurones after maximal voluntary contractions.

Authors:  Serajul I Khan; Sabine Giesebrecht; Simon C Gandevia; Janet L Taylor
Journal:  J Physiol       Date:  2012-08-20       Impact factor: 5.182

6.  The effects of passive exercise therapy initiated prior to or after the development of hyperreflexia following spinal transection.

Authors:  Charlotte C Yates; Amanda Charlesworth; Nancy B Reese; Robert D Skinner; Edgar Garcia-Rill
Journal:  Exp Neurol       Date:  2008-07-11       Impact factor: 5.330

7.  Acupuncture for the treatment of spasticity after stroke: a meta-analysis of randomized controlled trials.

Authors:  Si-Woon Park; Sook-Hee Yi; Jung Ah Lee; Pil Woo Hwang; Hyun Cheol Yoo; Kyoung Sook Kang
Journal:  J Altern Complement Med       Date:  2014-09       Impact factor: 2.579

8.  Spasticity and electrophysiologic changes after extracorporeal shock wave therapy on gastrocnemius.

Authors:  Min Kyun Sohn; Kang Hee Cho; Young-Jae Kim; Seon Lyul Hwang
Journal:  Ann Rehabil Med       Date:  2011-10-31

9.  The relation between Ashworth scores and neuromechanical measurements of spasticity following stroke.

Authors:  Laila Alibiglou; William Z Rymer; Richard L Harvey; Mehdi M Mirbagheri
Journal:  J Neuroeng Rehabil       Date:  2008-07-15       Impact factor: 4.262

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.